HANXBIO-B repurchases 29,500 H-shares for HKD 0.85 million, treasury stock climbs to 1.79 million shares

Bulletin Express07-06

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share buy-back on 6 July 2026, purchasing 29,500 H-shares on the Hong Kong Stock Exchange. The shares were repurchased within a price range of HKD 28.60 to HKD 29.20, at a volume-weighted average of HKD 28.96 per share, for a total consideration of HKD 0.85 million.

Post-transaction, the company’s issued share capital (excluding treasury shares) fell by 0.022 % to 134.43 million shares, while treasury shares increased to 1.79 million. The total number of issued shares remained unchanged at 136.22 million.

The repurchase forms part of the mandate approved by shareholders on 24 June 2026, which authorises HANXBIO-B to buy back up to 13.47 million shares. Cumulative repurchases under this mandate have reached 267,800 shares, representing 0.1988 % of the company’s issued shares on the approval date.

In line with Hong Kong listing rules, the company is subject to a 30-day moratorium on issuing new shares or selling treasury shares until 5 August 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124603704?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 19:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124603704","market":"us","top_or_hot":-1,"title":"HANXBIO-B repurchases 29,500 H-shares for HKD 0.85 million, treasury stock climbs to 1.79 million shares","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share buy-back on 6 July 2026, purchasing 29,500 H-shares on the Hong Kong Stock Exchange. The shares were repurchased within a price range of HKD 28.60 to HKD 29.20, at a volume-weighted average of HKD 28.96 per share, for a total consideration of HKD 0.85 million.</p>\n<p>Post-transaction, the company’s issued share capital (excluding treasury shares) fell by 0.022 % to 134.43 million shares, while treasury shares increased to 1.79 million. The total number of issued shares remained unchanged at 136.22 million.</p>\n<p>The repurchase forms part of the mandate approved by shareholders on 24 June 2026, which authorises HANXBIO-B to buy back up to 13.47 million shares. Cumulative repurchases under this mandate have reached 267,800 shares, representing 0.1988 % of the company’s issued shares on the approval date.</p>\n<p>In line with Hong Kong listing rules, the company is subject to a 30-day moratorium on issuing new shares or selling treasury shares until 5 August 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANXBIO-B repurchases 29,500 H-shares for HKD 0.85 million, treasury stock climbs to 1.79 million shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANXBIO-B repurchases 29,500 H-shares for HKD 0.85 million, treasury stock climbs to 1.79 million shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-06 19:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share buy-back on 6 July 2026, purchasing 29,500 H-shares on the Hong Kong Stock Exchange. The shares were repurchased within a price range of HKD 28.60 to HKD 29.20, at a volume-weighted average of HKD 28.96 per share, for a total consideration of HKD 0.85 million.</p>\n<p>Post-transaction, the company’s issued share capital (excluding treasury shares) fell by 0.022 % to 134.43 million shares, while treasury shares increased to 1.79 million. The total number of issued shares remained unchanged at 136.22 million.</p>\n<p>The repurchase forms part of the mandate approved by shareholders on 24 June 2026, which authorises HANXBIO-B to buy back up to 13.47 million shares. Cumulative repurchases under this mandate have reached 267,800 shares, representing 0.1988 % of the company’s issued shares on the approval date.</p>\n<p>In line with Hong Kong listing rules, the company is subject to a 30-day moratorium on issuing new shares or selling treasury shares until 5 August 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1124603704","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124603704","pubTimestamp":1783337060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share buy-back on 6 July 2026, purchasing 29,500 H-shares on the Hong Kong Stock Exchange. The shares were repurchased within a price...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"HANXBIO-B以85万港元回购2.95万股H股库存股攀升至179万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share buy-back on 6 July 2026, purchasing 29,500 H-shares on the Hong Kong Stock Exchange. The shares were repurchased within a price range of HKD 28.60 to HKD 29.20, at a volume-weighted average of HKD 28.96 per share, for a total consideration of HKD 0.85 million.\nPost-transaction, the company’s issued share capital (excluding treasury shares) fell by 0.022 % to 134.43 million shares, while treasury shares increased to 1.79 million. The total number of issued shares remained unchanged at 136.22 million.\nThe repurchase forms part of the mandate approved by shareholders on 24 June 2026, which authorises HANXBIO-B to buy back up to 13.47 million shares. Cumulative repurchases under this mandate have reached 267,800 shares, representing 0.1988 % of the company’s issued shares on the approval date.\nIn line with Hong Kong listing rules, the company is subject to a 30-day moratorium on issuing new shares or selling treasury shares until 5 August 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124603704","isCrawlerRequest":true}